Literature DB >> 18386228

RNAi therapeutics: an update on delivery.

Thu Nguyen1, Ellen M Menocal, Jens Harborth, Johannes H Fruehauf.   

Abstract

RNA interference (RNAi) has rapidly advanced from a laboratory observation into a major area of research within biology and medicine. RNAi is triggered by short interfering RNAs (siRNAs) of between 19 and 21 nucleotides in length, which induces the targeted cleavage of mRNA with sequences of homology to the siRNA. Because of its high degree of specificity and efficacy, the potential for RNAi-based therapeutics was recognized at an early stage. However, development of RNAi-based agents has been hindered because siRNAs are unstable in serum and delivery across the cell membrane is highly inefficient. Numerous methods have been developed to facilitate delivery of RNAi in animals and patients, each with their own set of advantages and disadvantages. This review discusses publications between 2005 to 2007 in the area of RNAi delivery, with a particular focus on in vivo application and clinical trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18386228

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  30 in total

1.  RNAi knockdown of PIK3CA preferentially inhibits invasion of mutant PIK3CA cells.

Authors:  Xin-Ke Zhou; Sheng-Song Tang; Gao Yi; Min Hou; Jin-Hui Chen; Bo Yang; Ji-Fang Liu; Zhi-Min He
Journal:  World J Gastroenterol       Date:  2011-08-28       Impact factor: 5.742

2.  Properties of Native High-Density Lipoproteins Inspire Synthesis of Actively Targeted In Vivo siRNA Delivery Vehicles.

Authors:  Kaylin M McMahon; Michael P Plebanek; C Shad Thaxton
Journal:  Adv Funct Mater       Date:  2016-09-20       Impact factor: 18.808

3.  RNA interference: A futuristic tool and its therapeutic applications.

Authors:  Anghesom Ambesajir; Atul Kaushik; Jeevan J Kaushik; Sham T Petros
Journal:  Saudi J Biol Sci       Date:  2012-08-17       Impact factor: 4.219

Review 4.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

Review 5.  Potential function of miRNAs in herpetic stromal keratitis.

Authors:  Sachin Mulik; Siddheshvar Bhela; Barry T Rouse
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-17       Impact factor: 4.799

6.  New core-shell nanoparticules for the intravenous delivery of siRNA to experimental thyroid papillary carcinoma.

Authors:  Henri de Martimprey; Jean-Rémi Bertrand; Claude Malvy; Patrick Couvreur; Christine Vauthier
Journal:  Pharm Res       Date:  2010-01-20       Impact factor: 4.200

Review 7.  Expression profiles and prognostic value of miRNAs in retinoblastoma.

Authors:  Lara Elis Alberici Delsin; Karina Bezerra Salomao; Julia Alejandra Pezuk; Maria Sol Brassesco
Journal:  J Cancer Res Clin Oncol       Date:  2018-10-22       Impact factor: 4.553

8.  Inhibition of monkeypox virus replication by RNA interference.

Authors:  Abdulnaser Alkhalil; Sarah Strand; Eric Mucker; John W Huggins; Peter B Jahrling; Sofi M Ibrahim
Journal:  Virol J       Date:  2009-11-04       Impact factor: 4.099

9.  First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder.

Authors:  Sancy A Leachman; Robyn P Hickerson; Mary E Schwartz; Emily E Bullough; Stephen L Hutcherson; Kenneth M Boucher; C David Hansen; Mark J Eliason; G Susan Srivatsa; Douglas J Kornbrust; Frances Jd Smith; Wh Irwin McLean; Leonard M Milstone; Roger L Kaspar
Journal:  Mol Ther       Date:  2009-11-24       Impact factor: 11.454

10.  PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer.

Authors:  G Munkácsy; R Abdul-Ghani; Z Mihály; B Tegze; O Tchernitsa; P Surowiak; R Schäfer; B Györffy
Journal:  Br J Cancer       Date:  2009-12-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.